Anna Morena D'Alise

Head of Immunology

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Anna Morena D'Alise is the Head of Immunology at Nouscom in Italy. Her research focuses on the development and efficacy of personalized cancer vaccines, particularly utilizing viral vectors and neoantigens to enhance antitumor T-cell responses. Recent publications highlight her work on novel strategies for cancer immunotherapy, including the optimization of adenoviral-based vaccines and the reprogramming of the tumor microenvironment for improved therapeutic outcomes.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Collaborators (3)

Nicola Zambrano

Full Professor of Molecular Biology

Università degli Studi di Napoli Federico II

ITALY

View details

Elisa Scarselli

Chief Scientific Officer

ITALY

View details

Katrina Pedersen

Assistant Professor

Washington University in Saint Louis School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anna Morena D'Alise

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Tumor burden dictates the neoantigen features required to generate an effective cancer vaccine.

Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses

Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine

Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer.

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy

Adenoviral-based vaccine promotes neoantigen-specific CD8<sup>+</sup> T cell stemness and tumor rejection

Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Collaborators (3)

Nicola Zambrano

Elisa Scarselli

Katrina Pedersen

Make your next move.